It is quite obvious that apelins that remain stable during enzymatic hydrolysis with a long half-life have the greatest prospects for clinical use in the treatment of stroke, acute myocardial infarction, and in the prevention of adverse myocardial remodeling. This evidence concerns the gene APLN and myocardial infarction.